AM-1220 is a drug that acts as a potent and moderately selective agonist for the cannabinoid receptor CB1, with around 19 times selectivity for CB1 over the related CB2 receptor. It was originally invented in the early 1990s by a team led by Thomas D’Ambra at Sterling Winthrop but has subsequently been researched by many others, most notably the team led by Alexandros Makriyannis at the University of Connecticut. The (piperidin-2-yl)methyl side chain of AM-1220 contains a stereocenter, so there are two enantiomers with quite different potency, the (R)-enantiomer having a Ki of 0.27 nM at CB1 while the (S)-enantiomer has a much weaker Ki of 217 nM
Chemical Structure
Synonyms
- [1-
[(1- methyl- 2- piperidinyl)methyl]- 1H- indol- 3- yl]- 1- naphthalenyl- methanone. cannabinoid drugs
AM1220 is a potent synthetic cannabinoid (CB) with preference for the central CB1 receptor (Ki = 3.88 nM) over the CB2 receptor (Ki = 73.4 nM). The physiological actions and metabolism of AM1220 have not been characterized. cannabinoid drugs
| Quantity | 10 g, 100 g, 500 g, 1kg |
|---|
Reviews
There are no reviews yet.
Related products
RESEARCH CHEMICALS
$150
Sale!
RESEARCH CHEMICALS
$255 – $2,300
RESEARCH CHEMICALS
$185
RESEARCH CHEMICALS
$150
Sale!
RESEARCH CHEMICALS
$200 – $2,050
RESEARCH CHEMICALS
$100
Sale!
RESEARCH CHEMICALS
$200 – $1,755
Sale!
RESEARCH CHEMICALS
$290 – $6,800
Be the first to review “AM-1220”